Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug 30;8(8):CD007697.
doi: 10.1002/14651858.CD007697.pub3.

Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer

Shaun Hiu  1 , Andrew Bryant  1 , Ketankumar Gajjar  2 , Patience T Kunonga  1 , Raj Naik  3
Affiliations
Meta-Analysis

Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer

Shaun Hiu et al. Cochrane Database Syst Rev. .

Abstract

Background: Ovarian cancer is the seventh most common cancer among women and the leading cause of death in women with gynaecological malignancies. Opinions differ regarding the role of ultra-radical (extensive) cytoreductive surgery in ovarian cancer treatment.

Objectives: To evaluate the effectiveness and morbidity associated with ultra-radical/extensive surgery in the management of advanced-stage epithelial ovarian cancer.

Search methods: We searched CENTRAL (2021, Issue 11), MEDLINE Ovid and Embase Ovid up to November 2021. We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies and contacted experts in the field.

Selection criteria: Randomised controlled trials (RCTs) or non-randomised studies (NRS), analysed using multivariate methods, that compared ultra-radical/extensive and standard surgery in women with advanced primary epithelial ovarian cancer.

Data collection and analysis: Two review authors independently assessed whether potentially relevant studies met the inclusion criteria, abstracted data and assessed the risk of bias. We identified three NRS and conducted meta-analyses where possible.

Main results: We identified three retrospective observational studies for inclusion in the review. Two studies included women exclusively undergoing upfront primary debulking surgery (PDS) and the other study including both PDS and interval debulking surgical (IDS) procedures. All studies were at critical risk of bias due to retrospective and non-randomised study designs. Meta-analysis of two studies, assessing 397 participants, found that women who underwent radical procedures, as part of PDS, may have a lower risk of mortality compared to women who underwent standard surgery (adjusted HR 0.60, 95% CI 0.43 to 0.82; I2 = 0%; very low-certainty evidence), but the evidence is very uncertain. The results were robust to a sensitivity analysis including women with more-extensive disease (carcinomatosis) (adjusted HR 0.61, 95% CI 0.44 to 0.85; I2 = 0%; n = 283, very low-certainty evidence), but the evidence is very uncertain. One study reported a comparison of radical versus standard surgical procedures associated with both PDS and IDS procedures, but a multivariate analysis was only undertaken for disease-free survival (DFS) and therefore the certainty of the evidence was not assessable for overall survival (OS) and remains very low. The lack of reporting of OS meant the study was at high risk of bias for selective reporting of outcomes. One study, 203 participants, found that women who underwent radical procedures as part of PDS may have a lower risk of disease progression or death compared to women who underwent standard surgery (adjusted HR 0.62, 95% CI 0.42 to 0.92; very low-certainty evidence), but the evidence is very uncertain. The results were robust to a sensitivity analysis in one study including women with carcinomatosis (adjusted HR 0.52, 95% CI 0.33 to 0.82; n = 139; very low-certainty evidence), but the evidence is very uncertain. A combined analysis in one study found that women who underwent radical procedures (using both PDS and IDS) may have an increased chance of disease progression or death than those who received standard surgery (adjusted HR 1.60, 95% CI 1.11 to 2.31; I2 = 0%; n = 527; very low-certainty evidence), but the evidence is very uncertain. In absolute and unadjusted terms, the DFS was 19.3 months in the standard surgery group, 15.8 in the PDS group and 15.9 months in the IDS group. All studies were at critical risk of bias and we only identified very low-certainty evidence for all outcomes reported in the review. Perioperative mortality, adverse events and quality of life (QoL) outcomes were either not reported or inadequately reported in the included studies. Two studies reported perioperative mortality (death within 30 days of surgery), but they did not use any statistical adjustment. In total, there were only four deaths within 30 days of surgery in both studies. All were observed in the standard surgery group, but we did not report a risk ratio (RR) to avoid potentially misleading results with so few deaths and very low-certainty evidence. Similarly, one study reported postoperative morbidity, but the authors did not use any statistical adjustment. Postoperative morbidity occurred more commonly in women who received ultra-radical surgery compared to standard surgery, but the certainty of the evidence was very low.

Authors' conclusions: We found only very low-certainty evidence comparing ultra-radical surgery and standard surgery in women with advanced ovarian cancer. The evidence was limited to retrospective, NRSs and so is at critical risk of bias. The results may suggest that ultra-radical surgery could result in improved OS, but results are based on very few women who were chosen to undergo each intervention, rather than a randomised study and intention-to-treat analysis, and so the evidence is very uncertain. Results for progression/DFS were inconsistent and evidence was sparse. QoL and morbidity was incompletely or not reported in the three included studies. A separate prognostic review assessing residual disease as a prognostic factor in this area has been addressed elsewhere, which demonstrates the prognostic effect of macroscopic debulking to no macroscopic residual disease. In order to aid existing guidelines, the role of ultra-radical surgery in the management of advanced-stage ovarian cancer could be addressed through the conduct of a sufficiently powered, RCT comparing ultra-radical and standard surgery, or well-designed NRSs, if this is not possible.

PubMed Disclaimer

Conflict of interest statement

SH: none known.

AB: none known.

PK: none known.

KG: performs surgery for advanced ovarian cancer surgery, but has no conflicts of interest to declare.

RN: performs surgery for advanced ovarian cancer surgery, but has no conflicts of interest to declare.

Figures

1
1
Study flow diagram up to 25 November 2021.
2
2
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
1.1
1.1. Analysis
Comparison 1: Ultra‐radical versus standard surgery (upfront surgery), Outcome 1: Survival
1.2
1.2. Analysis
Comparison 1: Ultra‐radical versus standard surgery (upfront surgery), Outcome 2: Survival: women with carcinomatosis (upfront surgery)
1.3
1.3. Analysis
Comparison 1: Ultra‐radical versus standard surgery (upfront surgery), Outcome 3: Progression‐free survival
1.4
1.4. Analysis
Comparison 1: Ultra‐radical versus standard surgery (upfront surgery), Outcome 4: Progression‐free survival: women with carcinomatosis (upfront surgery)
1.5
1.5. Analysis
Comparison 1: Ultra‐radical versus standard surgery (upfront surgery), Outcome 5: Disease‐free survival
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Aletti 2006a {published data only}
    1. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology 2006;107(1):77-85. - PubMed
Chang 2012a {published data only}
    1. Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology 2012;19(13):4059-67. - PubMed
Luyckx 2012 {published data only}
    1. Luyckx M, Leblanc E, Filleron T, Morice P, Darai E, Classe JM, et al. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study. International Journal of Gynecological Cancer 2012;22(8):1337-43. - PubMed
    1. Martinez A, Picaud L, Luyckx M, Pomel C, Leblanc E, Morice P, et al. Surgical approach and survival in elderly patients with advanced ovarian cancer. 15th Biennial Meeting of the International Gynecologic Cancer Society; 2014 Nov 8-11; Melbourne (VIC).

References to studies excluded from this review

Aletti 2006b {published data only}
    1. Aletti GD, Podratz KC, Jones MB, Cliby WA. Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons 2006;203(4):521-6. - PubMed
Aletti 2006c {published data only}
    1. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology 2006;100(2):283-7. - PubMed
Aletti 2009a {published data only}
    1. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope RC, Wilson TO, et al. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic Experience. Journal of the American College of Surgeons 2009;208:614-20. - PubMed
Aletti 2009b {published data only}
    1. Aletti GD, Podratz KC, Moriarity JP, Cliby WA, Long KH. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis. Gynecologic Oncology 2009;112:16-21. - PubMed
Angioli 2012 {published data only}
    1. Angioli R, Plotti F, Aloisi A, Capriglione S, Terranova C, Ricciardi R, et al. Does extensive upper abdomen surgery during primary cytoreduction impact on long-term quality of life? International Journal Gynecologic Cancer 2012;2012:E1014. - PubMed
Bahra 2013 {published data only}
    1. Bahra M, Fotopoulou C, Braicu EI, Kwee SL, Kuhberg M, Richter R, et al. Salvage surgery due to bowel obstruction in advanced or relapsed ovarian cancer resulting in short bowel syndrome and long-life total parenteral nutrition: surgical and clinical outcome. International Journal of Gynecologic Cancer 2013;23(8):1495-500. - PubMed
Barlin 2013 {published data only}
    1. Barlin JN, Long KC, Tanner EJ, Gardner GJ, Leitao MM, Levine DA, et al. Optimal. Gynecologic Oncology 2013;130(2):284-8. - PubMed
Bartl 2018 {published data only}
    1. Bartl T, Schwameis R, Stift A, Bachleitner-Hofmann T, Reinthaller A, Grimm C, et al. Predictive and prognostic implication of bowel resections during primary cytoreductive surgery in advanced epithelial ovarian cancer EMT. International Journal of Gynecological Cancer 2018;28(9):1664-71. - PubMed
Bertelsen 1990 {published data only}
    1. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecologic Oncology 1990;38(2):203-9. - PubMed
Bristow 1999 {published data only}
    1. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecologic Oncology 1999;72(3):278-87. - PubMed
Butler 2012 {published data only}
    1. Butler J, Watt J, Brockbank E, Pomel C, Jeyarajah A, Reynolds K, et al. Upper abdominal resections in gynaecological malignancy – the Barts experience. International Journal Gynecologic Cancer 2012;1:E1014.
Cai 2007 {published data only}
    1. Cai HB, Zhou YF, Chen HZ, Hou HY. The role of bowel surgery with cytoreduction for epithelial ovarian cancer. Clinical Oncology (Royal College of Radiologists) 2007;19(10):757-62. - PubMed
Campos 2014 {published data only}
    1. Campos Cascales P, Gil Jose, Parrilla Pascual. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer. European Journal of Surgical Oncology 2014;40(8):970-5. - PubMed
Canlorbe 2018 {published data only}
    1. Canlorbe G, Touboul C, Chargari C, Bentivegna E, Maulard A, Pautier P, et al. Transitory stoma at the time of complete cytoreductive surgery affects survival for patients with advanced-stage ovarian cancer. Anticancer research 2018;38(3):1517-23. - PubMed
Chang 2012b {published data only}
    1. Chang SJ, Bristow RE, Ryu HS. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology 2012;126(3):381-6. - PubMed
Chereau 2011 {published data only}
    1. Chereau E, Ballester M, Selle F, Rouzier R, Darai E. Ovarian cancer in the elderly: impact of surgery on morbidity and survival. European Journal of Surgical Oncology 2011;37(6):537-42. - PubMed
Chi 2004 {published data only}
    1. Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecologic Oncology 2004;94(3):650-4. - PubMed
Chi 2009 {published data only}
    1. Chi DS, Zivanovic O, Kolev V, Huh J, Joseph D, Leitao MM, et al. Incidence of major surgical complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal and peritoneal carcinomas. Gynecologic Oncology 2009;112(2):S2-3. - PubMed
Chua 2011 {published data only}
    1. Chua TC, Liauw W, Saxena A, Al-Mohaimeed K, Fransi S, Zhao J, et al. Evolution of locoregional treatment for peritoneal carcinomatosis: single-center experience of 308 procedures of cytoreductive surgery and perioperative intraperitoneal chemotherapy. American Journal of Surgery 2011;201(2):149-56. - PubMed
Clark 2012 {published data only}
    1. Clark RM, Growdon WB, Wiechert A, Carmen MG, Goodman A, Boruta DM, et al. Hospital readmission after surgical cytoreduction for epithelial ovarian carcinoma: an assessment of risk. Journal of Clinical Oncology 2012;30:15.
Clark 2014 {published data only}
    1. Clark RM, Clemmer JT, Melamed A, Rauh-Hain JA, Joseph N, Boruta DM, et al. Primary debulking surgery in stage IIIC and IV ovarian cancer results in improved survival compared to those undergoing neoadjuvant chemotherapy with interval cytoreduction. Gynecologic Oncology 2014;133:91-2.
Cormier 2012 {published data only}
    1. Cormier B, Long K, Ducie J, Tanner E, Wadhawan I, Jewell E, et al. Do patients with complete gross resection of advanced stage ovarian cancer benefit from lymphadenectomy? Gynecologic Oncology 2012;125:S24.
Cummins 2019 {published data only}
    1. Cummins C, Patrick H, Long J, Kumar S, Sundar S, Bramley G. Ultraradical ovarian cancer surgery comparative clinical effectiveness. International Journal of Technology Assessment in Health Care 2019;35:97.
Davies 2019 {published data only}
    1. Davies J, Asher V, Bali A, Abdul S, Gomez D, Tou S, et al. Impact of splenectomy on survival in advanced ovarian cancer (AOC) in a propensity matched cohort. International Journal of Gynecological Cancer 2019;29:A508-9.
Eisenhauer 2006 {published data only}
    1. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer. Gynecologic Oncology 2006;103(3):1083-90. - PubMed
Eisenkop 1993 {published data only}
    1. Eisenkop SM, Nalick RH, Wang HJ, Teng NN. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecologic Oncology 1993;51(2):224-9. - PubMed
Eisenkop 1998 {published data only}
    1. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology 1998;69(2):103-8. - PubMed
Eisenkop 2001 {published data only}
    1. Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecologic Oncology 2001;82(3):435-41. - PubMed
Eisenkop 2003 {published data only}
    1. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology 2003;90(2):390-6. - PubMed
Eisenkop 2006 {published data only}
    1. Eisenkop SM, Spirtos NM, Lin WC. Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer. Gynecologic Oncology 2006;100(2):344-8. - PubMed
Elgamal 2019 {published data only}
    1. Elgamal M, Saha S, Cherry M, Saharan V, Buttar R, Wiese D, et al. Prognostic implications of lymph node metastasis in advanced ovarian cancer: analysis of the National Cancer Database 2006 to 2014. Journal of Clinical Oncology 2019;37(15 Suppl):e17042-e17042.
Eng 2018 {published data only}
    1. Eng OS, Raoof M, Yu X, Lee SJ, Han ES, Wakabayashi MT, et al. Outcomes after upper abdominal debulking in ovarian malignancies. Annals of Surgical Oncology 2018;12(1):S138-9.
Eoh 2017 {published data only}
    1. Eoh KJ, Lee JY, Yoon JW, Nam EJ, Kim S, Kim SW, et al. Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: reappraisal in the era of radical surgery. Oncotarget 2017;8(23):37807-16. - PMC - PubMed
Falconer 2020 {published data only}
    1. Falconer H, Joneborg U, Krawiec K, Palsdottir K, Bottai M, Salehi S. Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population. Gynecologic Oncology 2020;159(1):58-65. - PubMed
Favero 2014 {published data only}
    1. Favero G, Macerox N, Pfiffer T, Ribeiro A, Miranda VC, Diz M, et al. Laparoscopic versus laparotomic cytoreduction in patients with advanced ovarian cancer submitted to NACT: evaluation of oncologic safety. Journal of Clinical Oncology 2014;32:15.
Ferrero 2014 {published data only}
    1. Ferrero A, Ditto A, Giorda G, Gadducci A, Greggi S, Daniele A, et al. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study. European Journal of Surgical Oncology 2014;40(7):891-8. - PubMed
Filippova 2019 {published data only}
    1. Filippova OT, Broach V, Gardner GJ, Sonoda Y, Zivanovic O, Chi DS, et al. Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: is interval debulking surgery truly less radical? Gynecologic Oncology 2019;154:142-3. - PMC - PubMed
Fotopoulou 2012 {published data only}
    1. Fotopoulou C, Braicu I, Vergote IB, Cadron I, Amant F, Chekerov R, et al. Interval versus primary tumor debulking surgery in advanced ovarian cancer: analysis of the European OVCAD data. Journal of Clinical Oncology 2012;30:5071.
Gockley 2019 {published data only}
    1. Gockley AA, Fiascone S, Hicks Courant K, Pepin K, Del Carmen M, Clark RM, et al. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma. International Journal of Gynecological Cancer 2019;29(3):585-92. - PubMed
Gremeau 2014 {published data only}
    1. Gremeau AS, Bourdel N, Jardon K, Rabischong B, Mage G, Pouly JL, et al. Surgical management of non-epithelial ovarian malignancies: advantages and limitations of laparoscopy. European Journal of Obstetrics & Gynecology and Reproductive Biology 2014;172:106-10. - PubMed
Grimm 2017 {published data only}
    1. Grimm C, Harter P, Alesina PF, Prader S, Schneider S, Ataseven B, et al. The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery. Gynecologic Oncology 2017;146(3):498-503. - PubMed
Guyon 2014 {published data only}
    1. Guyon F, Doublier M, Quincy P, Babin G, Floquet A. Surgical management of advanced ovarian cancer: what does the plasmajet brings? International Journal of Gynecological Cancer 2014;24:416.
Hamilton 2011 {published data only}
    1. Hamilton CA, Miller A, Miller C, Krivak TC, Farley JH, Chernofsky MR, et al. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecologic Oncology 2011;122(3):521-6. - PMC - PubMed
Hudry 2013 {published data only}
    1. Hudry D, Cannone F, Houvenaeghel G, Buttarelli M, Jauffret C, Chéreau E, et al. Comparison of single-port laparoscopy and conventional laparoscopy for extraperitoneal para-aortic lymphadenectomy. Surgical Endoscopy 2013;27(11):4319-24. - PubMed
Hwang 2014 {published data only}
    1. Hwang EC, Hwang I, Jung SI, Kang TW, Kwon DD, Heo SH, et al. Prognostic factors for recurrence-free and overall survival after adrenalectomy for metastatic carcinoma: a retrospective cohort pilot study. BMC Urology 2014;14(1):41. - PMC - PubMed
Janda 2014 {published data only}
    1. Janda M, Graves N, Bauer J, Baker J, Obermair A. Quality of life and nutritional status after early enteral feeding versus standard care after surgery for advanced epithelial ovarian cancer. International Journal of Gynecological Cancer 2014;24(9 Suppl 4):45.
Jiang 2013 {published data only}
    1. Jiang R, Yin S, Liu D, Wu X, Wang H, Li Z, et al. Extensive upper abdominal surgery for bulky stage IIIC and IV ovarian cancer: is it just a "belief"? 18th International Meeting of the European Society of Gynaecological Oncology, ESGO; 2013 Oct 19-22; Liverpool (UK).
Kato 2013a {published data only}
    1. Kato K, Tate S, Nishikimi K, Shozu M. Assessment of intraoperative tube thoracostomy after diaphragmatic resection as part of debulking surgery for primary advanced-stage Müllerian cancer. Gynecologic Oncology 2013;131(1):32-5. - PubMed
Kato 2013b {published data only}
    1. Kato K, Tate S, Nishikimi K, Shozu M. Bladder function after modified posterior exenteration for primary gynecological cancer. Gynecologic Oncology 2013;129(1):229-33. - PubMed
Kehoe 2013 {published data only}
    1. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener HC, Lopes T, et al. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. Journal of Clinical Oncology 2013;31:15.
Kim 2011 {published data only}
    1. Kim HS, Kim EN, Jeong SY, Chung HH, Kim YB, Kim JW, et al. Comparison of the efficacy of low anterior resection with primary anastomosis and Hartmann's procedure in advanced primary or recurrent epithelial ovarian cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology 2011;156(2):194-8. - PubMed
Kolev 2014 {published data only}
    1. Kolev V, Pereira EB, Schwartz M, Sarpel U, Roayaie S, Labow D, et al. The role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer. International Journal of Gynecologic Cancer 2014;24(1):70-4. - PubMed
Kommoss 2010 {published data only}
    1. Kommoss S, Rochon J, Harter P, Heitz F, Grabowski JP, Ewald-Riegler N. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Annals of Surgical Oncology 2010;17:279-86. - PubMed
Kristensen 2014 {published data only}
    1. Kristensen GS, Schledermann D, Mogensen O, Jochumsen KM. The value of random biopsies, omentectomy, and hysterectomy in operations for borderline ovarian tumors. International Journal of Gynecologic Cancer 2014;24(5):874-9. - PubMed
Kuhn 1998 {published data only}
    1. Kuhn W, Florack G, Roder J, Schmalfeldt B, Pache L, Rust M, et al. The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV. International Journal of Gynecological Cancer 1998;8(1):56-63.
Laios 2019 {published data only}
    1. Laios A, Kaufmann A, Otify M, Broadhead T, Hutson R, Nugent D, et al. The prognostic role of age, timing of surgery and surgical radicability in patients with advanced stage epithelial ovarian cancer; a single institution experience. International Journal of Gynecological Cancer 2019;119:A485.
Lee 2017 {published data only}
    1. Lee Y, Lu L, Xu W, Brown T, May T. Investigating the impact of interval from primary debulking surgery to initiation of adjuvant chemotherapy in advanced high-grade serous ovarian cancer. Gynecologic Oncology 2017;145:185.
Li 2014 {published data only}
    1. Li X, Xing H, Li L, Huang Y, Zhou M, Liu Q, et al. Clinical significance of para-aortic lymph node dissection and prognosis in ovarian cancer. Frontiers of medicine 2014;8(1):96-100. - PubMed
Liberale 2019 {published data only}
    1. Liberale G, Pop CF, Polastro L, Kerger J, Moreau M, Chintinne M, et al. A radical approach to achieve complete cytoreductive surgery improve survival of patients with advanced ovarian cancer. Journal of Visceral Surgery 2019;157:79-86. - PubMed
Liu 2013a {published data only}
    1. Liu Q, Ding X, Yang J, Cao D, Shen K, Lang J, et al. The significance of comprehensive staging surgery in malignant ovarian germ cell tumors. Gynecologic Oncology 2013;131(3):551-4. - PubMed
Liu 2013b {published data only}
    1. Liu Q, Ding XL, Yang JX, Cao DY, Shen K, Lang JH, et al. Multicenter randomized controlled clinical study for the operative treatment of malignant ovarian germ cell tumors. Zhonghua Fu Chan Ke za Zhi 2013;48(3):188-92. - PubMed
Martinez 2014 {published data only}
    1. Martinez A, Picaud L, Luyckx M, Pomel C, Leblanc E, Morice P, et al. Surgical approach and survival in elderly patients with advanced ovarian cancer. Journal of Ovarian Research 2014;1:297-8.
McCann 2011 {published data only}
    1. McCann CK, Growdon WB, Munro EG, Del Carmen MG, Boruta DM, Schorge JO, et al. Prognostic significance of splenectomy as part of initial cytoreductive surgery in ovarian cancer. Annals of Surgical Oncology 2011;18(10):2912-8. - PubMed
Muallem 2018 {published data only}
    1. Muallem MZ. Total retroperitoneal en bloc resection of peritoneal-multi visceral packet by advanced ovarian cancer. International Journal of Gynecological Cancer 2018;30:648-53. - PubMed
Oseledchyk 2016 {published data only}
    1. Oseledchyk A, Hunold LE, Mallmann MR, Domrose CM, Abramian A, Debald M, et al. Impact of extended primary surgery on suboptimally operable patients with advanced ovarian cancer. International Journal of Gynecological Cancer 2016;26(5):873-83. - PubMed
Oshita 2013 {published data only}
    1. Oshita T, Itamochi H, Nishimura R, Numa F, Takehara K, Hiura M, et al. Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group. International Journal of Clinical Oncology 2013;18(6):1107-13. - PubMed
Park 2011 {published data only}
    1. Park NH, Kim MK, Kim JW, Song YS, Kang SB. Effect of lymphadenectomy on survival outcomes in advanced epithelial ovarian cancer. 17th International Meeting of the European Society of Gynaecological Oncology, ESGO; 2011 Sep 11-14; Milan (Italy).
Pathiraja 2011 {published data only}
    1. Pathiraja PN, Eltz S, Garruto R, Spain G, Martinek I, Tozzi R. Evaluation surgical morbidity of diaphragmatic surgery with/without pleurectomy to achieve optimum cytoreduction in ovarian cancer. 17th International Meeting of the European Society of Gynaecological Oncology, ESGO, 11-14 September 2011. In: 17th International Meeting of the European Society of Gynaecological Oncology, ESGO; 2011 Sep 11-14; Milan (Italy).
Pathiraja 2013 {published data only}
    1. Pathiraja PN, Garruto-Campanile R, Tozzi R. Diaphragmatic peritonectomy versus full thickness diaphragmatic resection and pleurectomy during cytoreduction in patients with ovarian cancer. International Journal of Surgical Oncology 2013;2013:6. - PMC - PubMed
Pelissier 2018 {published data only}
    1. Pelissier A, Franke O, Darai E, Houvenaeghel G, Chereau E, Rouzier R. Value of diaphragmatic surgery during interval debulking surgery. Anticancer Research 2018;38(1):411-6. - PubMed
Perri 2013 {published data only}
    1. Perri T, Ben-Baruch G, Kalfon S, Beiner ME, Helpman L, Hogen LB, et al. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction? Gynecologic Oncology 2013;131(1):27-31. - PubMed
Phillips 2018 {published data only}
    1. Phillips A, Sundar S, Singh K, Pounds R, Nevin J, Kehoe S, et al. The NICE classification for 'Ultra-radical (extensive) surgery for advanced ovarian cancer' guidance does not meaningfully predict postoperative complications: a cohort study. BJOG 2018;126:96-104. - PubMed
Pushpalatha 2011 {published data only}
    1. Pushpalatha K, Kumar KS, Kumar L, Julka PK, Mathur S. Impact of pelvic lymphadenectomy during primary cytoreductive surgery on survival in epithelial ovarian cancer: a prospective study. Journal of Clinical Oncology 2011;29(15 Suppl):e15563.
Qin 2012 {published data only}
    1. Qin JC, Yang ZJ, Xiong L, Li L. Systematic lymphadenectomy for overall survival in epithelial ovarian cancer: a meta-analysis. Chinese Journal of Evidence-Based Medicine 2012;12(2):224-30.
Ratnavelu 2014 {published data only}
    1. Ratnavelu N, Biliatis I, Patel A, Founta C, Kucukmetin A, Naik R. Total colectomy to achieve cytoreduction in advanced ovarian cancer: a three-arm matched cohort study. Gynecologic Oncology 2014;114:450-1.
Ren 2015 {published data only}
    1. Ren Y, Jiang R, Yin S, You C, Liu D, Cheng X, et al. Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study. BMC Cancer 2015;15(1):583. - PMC - PubMed
Rodriguez 2012 {published data only}
    1. Rodriguez N, Miller A, Richard S, Rungruang B, Hamilton C, Bookman M, et al. Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of GOG 182. 43rd Annual Meeting of the Society of Gynecologic Oncology; 2012 Mar 24-27; Austin (TX). - PubMed
Rodriguez 2013 {published data only}
    1. Rodriguez N, Miller A, Richard SD, Rungruang B, Hamilton CA, Bookman MA, et al. Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. Gynecologic Oncology 2013;130(3):487-92. - PubMed
Rouzier 2010 {published data only}
    1. Rouzier R, Bergzoll C, Brun JL, Dubernard G, Selle F, Uzan S, et al. The role of lymph node resection in ovarian cancer: analysis of the Surveillance, Epidemiology, and End Results (SEER) database. BJOG 2010;117(12):1451-8. - PubMed
Sagara 2019 {published data only}
    1. Sagara A, Motohara T, Iwagoi Y, Saito F, Takaishi K, Miyahara Y, et al. Survival impact of wide resection of the pelvic peritoneum in patients with epithelial ovarian cancer. International Journal of Gynecological Cancer 2019;29:A515.
Sandadi 2014 {published data only}
    1. Sandadi S, Long K, Andikyan V, Vernon J, Zivanovic O, Eisenhauer EL, et al. Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer. Gynecologic Oncology 2014;132(2):299-302. - PubMed
Scalici 2014 {published data only}
    1. Scalici JM, DeCotis-Smith D, Wang B, Finan MA, Rocconi RP. A comparative analysis of the treatment strategies for advanced ovarian cancer. Gynecologic Oncology 2014;133:60-1.
Sehouli 2010 {published data only}
    1. Sehouli J, Savvatis K, Braicu EI, Schmidt SC, Lichtenegger W, Fotopoulou C. Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis. International Journal of Gynecologic Cancer 2010;20(8):1331-40. - PubMed
Soo Hoo 2015 {published data only}
    1. Soo Hoo S, Marriott N, Houlton A, Nevin J, Balega J, Singh K, et al. Patient-reported outcomes after extensive (ultraradical) surgery for ovarian cancer: results from a prospective longitudinal feasibility study. International Journal of Gynecological Cancer 2015;25(9):1599-607. - PubMed
Stefanović 2011 {published data only}
    1. Stefanović A, Jeremić K, Kadija S, Milincić N, Mircić A, Petković S, et al. Intestinal surgery in treatment of advanced ovarian cancer review of our experience. European Journal of Gynaecological Oncology 2011;32(4):419-22. - PubMed
Sundar 2014 {published data only}
    1. Sundar S. Quality of life in patients undergoing extensive (radical/ ultraradical surgery) for ovarian cancer – the SOCQER-1 study. International Journal of Gynecological Cancer 2014;9:15.
Sundar 2018 {published data only}
    1. Sundar S, Kumar S, Long J, Balega J, Fotopoulou C, Broadhead T, et al. Patient reported outcomes (PRO) after surgery in advanced ovarian cancer-initial results from the international, prospective, multicenter SOCQER 2 study. International Journal of Gynecological Cancer 2018;24:604-6.
Sundar 2019 {published data only}
    1. Sundar S, Cummins C, Kumar S, Long J, Arora V, Balega J, et al. Quality of life after surgery of varying surgical complexity in advanced ovarian cancer: results from the international, prospective, multicenter cohort SOCQER2 study. International Journal of Gynecological Cancer 2019;24:A638-9.
Suzuki 2008 {published data only}
    1. Suzuki S, Kajiyama H, Shibata K, Ino K, Nawa A, Sakakibara K, et al. Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients? Annals of Oncology 2008;19(7):1284-7. - PubMed
Szczesny 2016 {published data only}
    1. Szczesny W, Vistad I, Kaern J, Nakling J, Trope C, Paulsen T. Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival. European Journal of Gynaecological Oncology 2016;37(3):305-11. - PubMed
Tozzi 2019 {published data only}
    1. Tozzi R, Casarin J, Baysal A, Garruto-Campanile R, Majd HS, Kilic Y, et al. Morbidity of multiple bowel resection compared to single bowel resection after debulking surgery for ovarian cancer. BJOG 2019;126:98. - PubMed
Tsolakidis 2010a {published data only}
    1. Tsolakidis D, Amant F, Van Gorp T, Leunen K, Neven P, Vergote I. The role of diaphragmatic surgery during interval debulking after neoadjuvant chemotherapy. International Journal of Gynecological Cancer 2010;20:542-51. - PubMed
Tsolakidis 2010b {published data only}
    1. Tsolakidis D, Amant F, Gorp T, Leunen K, Neven P, Vergote I. Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB-IV epithelial ovarian cancer. Gynecologic Oncology 2010;116:489-96. - PubMed
van de Laar 2014 {published data only}
    1. de Laar R, Zusterzeel PL, Gorp T, Buist MR, Driel WJ, Gaarenstroom KN, et al. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study. BMC Cancer 2014;14(1):22. - PMC - PubMed
Vidal 2016 {published data only}
    1. Vidal F, Al Thani H, Haddad P, Luyckx M, Stoeckle E, Morice P, et al. Which surgical attitude to choose in the context of non-resectability of ovarian carcinomatosis: beyond gross residual disease considerations. Annals of Surgical Oncology 2016;23(2):434-42. - PubMed
von Hugo 1989 {published data only}
    1. Hugo R, Holscher M, Janicke F. Morbidity, mortality and quality of life following radical surgical interventions in advanced ovarian cancer. Archives of Gynecology & Obstetrics 1989;245(1-4):625-7. - PubMed
Wallace 2016 {published data only}
    1. Wallace S, Kumar A, Mc Gree M, Weaver A, Cliby W. Residual disease after primary cytoreduction in stage IIIC ovarian cancer; is aggressive cytoreduction worth it? Gynecologic Oncology 2016;143(1):206.
Wat 2012 {published data only}
    1. Wat J, Butler J, Brockbank E, Pomel C, Jeyarajah A, Rosenthal A, et al. Upper abdominal resections in gynaecological malignancy – the Barts experience. Official Journal of the International Hepato Pancreato Biliary Association 2012;32:E1014.
Wimberger 2007 {published data only}
    1. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecologic Oncology 2007;106(1):69-74. - PubMed
Wright 2012 {published data only}
    1. Wright JD, Herzog TJ, Neugut AI, Burke WM, Lu YS, Lewin SN, et al. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer. Obstetrics & Gynecology 2012;120(4):871-81. - PubMed
Yildirim 2014 {published data only}
    1. Yildirim Y, Ertas IE, Nayki U, Ulug P, Nayki C, Yilmaz I, et al. En-bloc pelvic resection with concomitant rectosigmoid colectomy and immediate anastomosis as part of primary cytoreductive surgery for patients with advanced ovarian cancer. European Journal of Gynaecological Oncology 2014;35(4):400-7. - PubMed
Zamurovic 2013 {published data only}
    1. Zamurovic M, Soldo V, Cutura N. Survival rate analysis of patients with advanced ovarian cancer treated according to different protocols. Internet Journal of Oncology 2013;9(1):629-36.
Zapardiel 2012 {published data only}
    1. Zapardiel I, Peiretti M, Zanagnolo V, Biffi R, Bocciolone L, Landoni F, et al. Splenectomy as part of primary cytoreductive surgery for advanced ovarian cancer: a retrospective cohort study. International Journal of Gynecological Cancer 2012;22(6):968-73. - PubMed

Additional references

Altman 1995
    1. Altman DG, Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. British Journal of Cancer 1995;72:511-8. - PMC - PubMed
American Cancer Society 2020
    1. American Cancer Society. Cancer facts & figures 2020. www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statisti... (last accessed 5 August 2022).
Bast 2020
    1. Bast RC Jr, Lu Z, Han CY, Lu KH, Anderson KS, Drescher CW, et al. Biomarkers and strategies for early detection of ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention 2020;29(12):2504-12. - PMC - PubMed
Benedetti Panici 2015
    1. Benedetti Panici P, Donato Di V, Fischetti M, Casorelli A, Perniola G, Musella A, et al. Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: analysis and management of complications in upper abdominal surgery. Gynecologic Oncology 2015;137(3):406-11. - PubMed
Berek 2018
    1. Berek JS, Kehoe ST, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynaecology and Obstetrics 2018;143:59-78. - PubMed
Bristow 2002
    1. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology 2002;20:1248-59. - PubMed
Bristow 2003
    1. Bristow RE, Carmen MG, Kaufman HS, Montz FJ. Radical oophrectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. Journal of the American College of Surgeons 2003;197:565-74. - PubMed
Bryant 2021
    1. Bryant A, Hiu S, Kunonga P, Gajjar K, Craig D, Vale L, et al. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. Cochrane Database of Systematic Reviews 2021, Issue 9. Art. No: CD015048. [DOI: 10.1002/14651858.CD015048] - DOI - PMC - PubMed
Chen 1985
    1. Chen SS, Bochner R. Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma. Gynecologic Oncology 1985;20:190-5. - PubMed
Colombo 2019
    1. Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology 2019;30(5):672-705. - PubMed
Covens 2000
    1. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecologic Oncology 2000;78:269-74. - PubMed
Crawford 2005
    1. Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. Journal of Clinical Oncology 2005;23:8802-11. - PubMed
CRUK 2018
    1. Cancer Research UK. Types of ovarian cancer. www.cancerresearchuk.org/about-cancer/ovarian-cancer/types (last accessed 5 August 2022).
CTCAE 2017
    1. CTCAE. Common terminology criteria for adverse events (CTCAE) v5.0, 2017. ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v... (last accessed 5 August 2017).
Deeks 2001
    1. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, editors(s). Systematic Reviews in Health Care: Meta-Analysis in Context (2nd edition). London (UK): BMJ Publication Group, 2001.
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88. - PubMed
EUROCARE 2015
    1. Sant M, Chirlaque Lopez MD, Agresti R, Sánchez Pérez MJ, Holleczek B, Bielska-Lasota M, et al, EUROCARE-5 Working Group. Survival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EUROCARE-5 study. European Journal of Cancer 2015;51(15):2191-205. - PubMed
GLOBOCAN 2018
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians 2018;68(6):394-424. - PubMed
Goodacre 2015
    1. Goodacre S. Uncontrolled before-after studies: discouraged by Cochrane and the EMJ. Emergency Medicine Journal 2015;32:507-8. - PubMed
GRADE Working Group 2004
    1. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490-4. - PMC - PubMed
Harley 2014
    1. Harley IJ, Quinn J, Beirne JP, McCluggage WG. The distal fallopian tube as the origin of non-uterine pelvic high-grade serous carcinomas; scientific paper No. 44, 2014. www.rcog.org.uk/media/s0nlcrlx/sip44hgscs.pdf (last accessed 5 August 2022).
Harter 2019
    1. Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. New England Journal of Medicine 2019;380(9):822-32. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. - PMC - PubMed
Higgins 2019
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated August 2019). Cochrane, 2019. training.cochrane.org/handbook/archive/v6.
Horowitz 2015
    1. Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. Journal of Clinical Oncology 2015;33(8):937-43. - PMC - PubMed
Hoskins 1992
    1. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecological Oncology 1992;47:159-66. - PubMed
Jaeger 2001
    1. Jaeger W, Ackermann S, Kessler H, Katalinic A, Lang N. The effect of bowel resection on survival in advanced epithelial ovarian cancer. Gynecologic Oncology 2001;83:286-91. - PubMed
Johnson 2008
    1. Johnson NP, Selman T, Zamora J, Khan KS. Gynaecologic surgery from uncertainty to science: evidence-based surgery is no passing fad. Human Reproduction 2008;23(4):832-9. - PubMed
Kehoe 2015
    1. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015;386(9990):249-57. - PubMed
Kirby 2020
    1. Kirby T. Confronting a rare ovarian cancer during lockdown. Lancet Respiratory Medicine 2020;8(12):1176-8. - PubMed
Kumar 2019
    1. Kumar S, Long J, Kehoe S, Sundar S, Cummins C. Quality of life outcomes following surgery for advanced ovarian cancer: a systematic review and meta-analysis. International Journal of Gynecological Cancer 2019;29(8):1285-91. - PubMed
Kurman 2008
    1. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IM. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. American Journal of Obstetrics and Gynecology 2008;198(4):351-6. - PMC - PubMed
Kurman 2014
    1. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organ. Lyon (France): IARC Press, 2014.
Kyriacou 2016
    1. Kyriacou DN, Lewis RJ. Confounding by indication in clinical research. JAMA 2016;316(17):1818-9. - PubMed
Lancet 2007
    1. Editorial. An experiment in earlier detection of ovarian cancer. Lancet 2007;369(9579):2051. - PubMed
Markman 2007
    1. Markman M. Concept of optimal cytoreduction in advanced ovarian cancer: a brief critique and a call for action. Journal of Clinical Oncology 2007;25(27):4168-70. - PubMed
Merideth 2003
    1. Merideth MA, Cliby WA, Keeney GL, Lesnick TG, Nagorney DM, Podratz KC. Hepatic resection for metachronous metastases from ovarian cancer. Gynecologic Oncology 2003;89:16-21. - PubMed
Montz 1989
    1. Montz FJ, Schlaerth JB, Berek JS. Resection of diaphragmatic peritoneum and muscle: role in cytoreductive surgery for ovarian cancer. Gynecologic Oncology 1989;35:338-40. - PubMed
NICE 2013
    1. National Institute for Health and Care Excellence. Ultra-radical (extensive) surgery for advanced ovarian cancer, 2013. www.nice.org.uk/guidance/ipg470 (last accessed 5 August 2022).
Norell 2020
    1. Norell CH, Butler J, Farrell R, Altman A, Bentley J, Cabasag CJ, et al. Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care. International Journal of Gynecological Cancer 2020;30(11):1748-56. - PMC - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34. - PubMed
PDQ Adult Treatment Editorial Board 2021
    1. PDQ Adult Treatment Editorial Board. Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment (PDQ®), 2021. www.ncbi.nlm.nih.gov/books/NBK66007/ (last accessed 5 August 2022).
Phillips 2019
    1. Phillips A, Sundar S, Singh K, Pounds R, Nevin J, Kehoe S, et al. The NICE classification for 'Ultra-radical (extensive) surgery for advanced ovarian cancer' guidance does not meaningfully predict postoperative complications: a cohort study. BJOG 2019;126:96-104. - PubMed
Pomel 2004
    1. Pomel C, Dauplat J. Management of malignant epithelial tumours of the ovary. Journal de Chirurgie 2004;141:277-84. - PubMed
Prat 2014
    1. Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynecological Cancer 2014;124(1):1-5. - PubMed
Rani 2018
    1. Rani G, Bandupadhyay S, Medhi AC, Shafi F. Ovarian cancer screening. Journal of Medical Science and Clinical Research 2018;6(5):1042-4.
Review Manager 2014 [Computer program]
    1. Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Schisterman 2009
    1. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 2009;20(4):488-95. - PMC - PubMed
Siegel 2020
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: a Cancer Journal for Clinicians 2020;70(1):7-30. - PubMed
Sterne 2016
    1. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919. - PMC - PubMed
Sterne 2022
    1. Sterne JA, Hernán MA, McAleenan A, Reeves BC, Higgins JP. Chapter 25: Assessing risk of bias in a non-randomized study. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.
Sundar 2021
    1. Sundar S, Cummins C, Kumar S, Long J, Arora V, Balega J, et al. Quality of life from cytoreductive surgery in advanced ovarian cancer: investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study. International Journal of Obstetrics and Gynaecology 2021;129:1122-32. - PMC - PubMed
Taggart 2001
    1. Taggart DP, D'Amico R, Altman DG. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet 2001;358(9285):870-5. - PubMed
Todo 2003
    1. Todo Y, Sakuragi N, Oikawa M, Negishi H, Yamamoto R, Yoshiaki K, et al. Cytoreductive surgery combined with organ resection for advanced ovarian cancer. International Journal of Clinical Oncology 2003;8:90-6. - PubMed
van Dam 1996
    1. Dam PA, Tjalma W, Weyler J. Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: a prospective randomised trial. Obstetrics and Gynecology 1996;174:943-50. - PubMed
Venesmaa 1992
    1. Venesmaa P, Ylikorkala O. Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstetrics and Gynecology 1992;79:168-72. - PubMed
Vergote 2010
    1. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine 2010;363(10):943-53. [Incl. Supplementary Appendix and Protocol] - PubMed
Vergote 2016
    1. Vergote I, Vlayen J, Heus P, Hoogendam JP, Damen JA, de Wetering F, et al. Ovarian cancer: diagnosis, treatment and follow-up, 2016. Good Clinical Practice (GCP) Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 268. D/2016/10.273/49.
Visintin 2008
    1. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clinical Cancer Research 2008;14:1065-72. - PubMed
Webb 2017
    1. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Practice & Research. Clinical Obstetrics & Gynaecology 2017;41:3-14. - PubMed
Zijlstra 2019
    1. Zijlstra M, Timmermans M, Fransen H, Aa M, Reyners A, Raijmakers N, et al. Treatment patterns and associated factors in patients with advanced epithelial ovarian cancer: a population-based study. International Journal of Gynecolological Cancer 2019;29:1032-7. - PubMed

References to other published versions of this review

Ang 2009
    1. Ang C, Chan KK, Naik R, Bryant A, Dickinson HO. Ultraradical surgery for the primary debulking of epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No: CD007697. [DOI: 10.1002/14651858.CD007697] - DOI - PMC - PubMed
Ang 2011
    1. Ang C, Chan KK, Bryant A, Naik R, Dickinson HO. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2011, Issue 4. Art. No: CD007697. [DOI: 10.1002/14651858.CD007697.pub2] - DOI - PMC - PubMed

MeSH terms